The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial.
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Jenny Hardingham
No relevant relationships to disclose
Chee Lee
No relevant relationships to disclose
Joe Wrin
No relevant relationships to disclose
Amanda Rose Townsend
No relevant relationships to disclose
Kate Wilson
No relevant relationships to disclose
Andrew James Weickhardt
No relevant relationships to disclose
John Simes
No relevant relationships to disclose
Carmel Murone
No relevant relationships to disclose
Niall Christopher Tebbutt
Consultant or Advisory Role - Roche (U)